UPC_CFI_808/2025

DETECTION AND TREATMENT OF DISEASE EXHIBITING DISEASE CELL HETEROGENEITY AND SYSTEMS AND METHODS FOR COMMUNICATING TEST RESULTS

Einstweilige MaßnahmenEinstweilige MaßnahmenParis LDProvisional measuresOral Phase

Übersicht Entscheidungen Begründung Zitate Dokumente Zeitverlauf

Parteien

Kläger

Guardant Health, Inc.

Vertreter: Agathe Michel-De Cazotte (Carpmaels & Ransford); Cameron Marshall (Carpmaels & Ransford); Caroline Horstmann

Beklagte

Sophia Genetics SA
Sophia Genetics SAS
Sophia Genetics SRL
Sophia Genetics GmbH

Vertreter: Liz Cohen (Bristows (Ireland) LLP); Naoise Gaffney (Bristows (Ireland) LLP); Rachael Cartwright (Bristows (Ireland) LLP)

Richter

Französische Kammer — Einzelrichter anonymisiert.

Panel member (anonymized)
Panel member (anonymized)
Panel member (anonymized)
Panel member (anonymized)

Patente

EP3766986
EP3470533
EP3443066
EP3591073
EP 3 591 073
EP 3 443 066
EP 3 766 986
EP 3 470 533

CPC-Codes: C12Q1/6827, G16B30/00, C12Q2600/118, C12Q1/6886, C12N15/11, C12Q2600/156, C12Q1/6869

Sektor: Biotechnology

Ausgang

PI abgelehnt

Eingereicht: 29. Aug. 2025

Erste Entscheidung: 1. Okt. 2025

Letzte Entscheidung: 23. Jan. 2026

Sprache: English

The Paris Local Division rejected Guardant Health's application for provisional measures under three patents (EP 3 591 073, EP 3 443 066, EP 3 766 986) against Sophia Genetics. The court found issues of added matter in the divisional patent and insufficient evidence to demonstrate infringement with the required degree of certainty. Guardant Health's request regarding a fourth patent (EP 3 470 533) was withdrawn during proceedings. Guardant Health ordered to pay Sophia Genetics EUR 400,000 as interim costs.

Im UPC-Register öffnen